Although the quality of palliative care in England and the wider UK is regarded as excellent, many patients receiving palliative care die in pain. This new study estimates that more than 5,000 patients would die in pain every year even under the ‘best practice’ palliative care such as that provided in hospices.
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long-run.